title: Targeting epigenetic programs in MLL-rearranged leukemias.
abstract: Rearrangements of the Mixed-Lineage Leukemia (MLL) gene are found in > 70% of infant leukemia, ~ 10% of adult acute myelogenous leukemia (AML), and many cases of secondary acute leukemias. The presence of an MLL rearrangement generally confers a poor prognosis. There are more than 60 known fusion partners of MLL having some correlation with disease phenotype and prognosis. The most common fusion proteins induce the inappropriate expression of homeotic (Hox) genes, which, during normal hematopoiesis, are maintained by wild-type MLL. MLL-rearranged leukemias display remarkable genomic stability, with very few gains or losses of chromosomal regions. This may be explained by recent studies suggesting that MLL-rearranged leukemias are largely driven by epigenetic dysregulation. Several epigenetic regulators that modify DNA or histones have been implicated in MLL-fusion driven leukemogenesis, including DNA methylation, histone acetylation, and histone methylation. The histone methyltransferase DOT1L has emerged as an important mediator of MLL-fusion-mediated leukemic transformation. The clinical development of targeted inhibitors of these epigenetic regulators may therefore hold promise for the treatment of MLL-rearranged leukemia.
authors.affiliation: Division of Hematology/Oncology, Children's Hospital, Boston, MA 02215, USA. Scott.Armstrong@childrens.harvard.edu
authors.forename: Kathrin M
authors.initials: KM
authors.lastname: Bernt
authors.forename: Scott A
authors.initials: SA
authors.lastname: Armstrong
mesh_terms: D019175:DNA Methylation / Q000235:genetics; D044127:Epigenesis, Genetic; D015973:Gene Expression Regulation, Leukemic; D015321:Gene Rearrangement / Q000235:genetics*; D006801:Humans; D007938:Leukemia / Q000235:genetics*; D051788:Myeloid-Lymphoid Leukemia Protein / Q000235:genetics*
chemical_list: D051788:Myeloid-Lymphoid Leukemia Protein